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TO THE EDITOR
Recommendations by the Centers for Disease Control and Prevention (CDC) (1) have 
expanded screening for hepatitis C virus (HCV) from those at increased risk for infection to 
the entire age cohort born during 1945–1965. This recommendation was based on the 
relatively high risk for infection in this group. Consideration was given to benefit versus risk 
for the individual patient as well as a cost analysis for screening the age cohort population 
(2). However, the cost analysis should have been performed for a different population: the 
group that was added to the screening recommendations—those in the age cohort who are 
not at increased risk for infection.
This age cohort has a relatively high incidence of HCV, but a large portion of the infected 
persons is derived from the relatively small group of those who are at high risk. Although 
numerous risk factors are listed, an earlier study (3) reported that one half of the risk for 
HCV infection for persons between the ages of 20 and 59 years comes from the 1.1% who 
had ever injected illicit drugs. Adding the 3.4% who received a transfusion before 1992 and 
the 6.1% with 20 or more lifetime sexual partners accounts for three quarters of the risk for 
HCV infection. If persons with an elevated alanine amino-transferase level are also tested, 
93.5% of the HCV-infected population would be identified.
In justifying the new guidelines, the CDC states that the accuracy of patient recall of risk 
behaviors decreases over time, but this assumption is based on a meta-analysis about HIV-
infected patients that compared 1-, 3-, and 6-month recall (4). Of interest, for “heroin use” 
and “number of sex partners,” 6-month recall was the best. This assumption of poor recall 
for healthy patients being considered for HCV screening is not adequately evidence-based. I, 
for one, born in 1956, am confident that I would remember if I had ever injected drugs, 
received a blood transfusion, or had 20 or more sexual partners.
If the high-risk group is excluded from the age cohort, the result is a large population with a 
low risk for infection. I suspect that a cost analysis of screening for HCV of this low-risk 
population would find it not to be cost-effective. In addition, the benefit versus risk of 
screening this low-risk population would need to be considered.
The key point is that the CDC has added this large population—those born during 1945–
1965 who are not at increased risk—to their recommendations for HCV screening. This 
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recommendation would result in the screening of millions of additional persons and cost 
billions of dollars. Before this step is taken, cost-effectiveness studies and benefit-versus-risk 
analyses should be done for this low-risk population. At this point, what screening should be 
recommended to an individual patient who reliably claims not to be at increased risk for 
HCV is unclear.
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